Filter articles using the following links

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics to participate in multiple upcoming investor conferences

Salon Actionaria 2018, Paris, France

2nd Annual Gene Therapy for Rare Disorders Europe, London, UK

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

Ophthalmology Innovation Summit @ AAO, Chicago (IL)

American Academy of Ophthalmology, Chicago (IL)

Chardan 2nd Annual Genetic Medicines Conference, NYC (US)

GenSight Biologics Reports Interim Financial Results for the First Half of 2018